Recent progress on third generation covalent EGFR inhibitors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• First-generation EGFR inhibitors (gefitinib, erlotinib) show efficacy in NSCLC with EGFR mutations (L858R, exon 19 deletions).
• Drug resistance, often due to the EGFR-T790M mutation, limits long-term treatment success in approximately 60% of patients.

Purpose of the Study:

• To review third-generation covalent EGFR inhibitors for NSCLC treatment.
• To discuss novel drug discovery methodologies for these advanced inhibitors.

Main Methods:

• Literature review of clinical trials involving third-generation EGFR inhibitors.
• Analysis of drug discovery approaches for novel covalent EGFR inhibitors.

Main Results:

• Third-generation covalent EGFR inhibitors exhibit high potency against T790M mutants.
• These inhibitors demonstrate selectivity over wild-type (WT) EGFR, minimizing off-target effects.

Conclusions:

• Third-generation EGFR inhibitors represent a promising therapeutic strategy for NSCLC patients with T790M-mediated resistance.
• Ongoing research and novel discovery methods are crucial for developing next-generation EGFR-targeted therapies.